Organization
ChosenMed Technology (Zhejiang) Co., Ltd.
6 abstracts
Abstract
Gene expression-based machine learning approach to predict immunotherapy response and survival in patients with advanced cancer.Org: ChosenMed Technology (Zhejiang) Co., Ltd.,
Abstract
Predicting the immunotherapy response based on molecular subtypes of pan-immune signatures in gastrointestinal stromal tumor.Org: ChosenMed Technology (Zhejiang) Co., Ltd., Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
Comprehensive genomic and transcriptomic profiling analysis of the recurrent gastrointestinal stromal tumor (GIST).Org: ChosenMed Technology (Zhejiang) Co., Ltd., Chinese People’s Liberation Army General Hospital, Beijing Tongren Hospital, Siping Central People’s Hospital,
Abstract
Association of a deep learning system with progression-free survival (PFS) in patients with renal cell carcinoma (RCC) treated with immune checkpoint blockades (ICBs).Org: The First Affiliated Hospital of University of Science and Technology of China, ChosenMed Technology (Zhejiang) Co., Ltd.,
Abstract
Circulating tumor DNA (ctDNA) methylation-based linkage regions to predict recurrence in early-stage lung cancer.Org: Qilu Hospital of Shandong University, ChosenMed Technology (Zhejiang) Co., Ltd., The Affiliated Hospital of Qingdao University, Shengli Oilfield Central Hospital, Zibo Central Hospital,
Abstract
A robust and accurate method to detect MET Exon 14–skipping mutation in pan-cancer samples using an NGS-based RNAseq approach.Org: ChosenMed Technology (Beijing) Co.Ltd, ChosenMed Technology (Beijing) Co., Ltd., ChosenMed Technology (Zhejiang) Co., Ltd.,